GGrantIndex
← Leaderboards

Courtney A Miller

University Of Florida

Google Scholar ↗PubMed ↗ORCID ↗
$16,288,628
Attributed
$31,275,273
Total exposure
23
Grants
17
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $3.6M · FY2007–25
$5M$3.8M$2.5M$1.3M$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$31,275,273 · 23

By mechanism

R01$18,163,032 · 5
U01$3,330,990 · 1
R21$2,442,106 · 5
R33$1,937,385 · 2
UH3$1,763,827 · 1
R42$811,876 · 1

Top collaborators

Most similar at University Of Florida

Same institution · by research overlap

Others in their field

Top investigators on “Pharmaceutical Preparations”

Research focus

Pharmaceutical PreparationsIn VivoBaseLearningBrainSynapsesInnovationAmygdaloid StructureNeuronsRelapseMemoryResponseBehaviorMolecularTherapeutic TargetPropertyActinsAreaMyosin Type IiPreventStructureDrug UsageDoseAnimal Model

Grant awards (70)

Preclinical development of a precision therapy for a monogenic mental health disorder$1,806,486
U01 · FY2025 · MH · contact PI
Intersection of causal neurodevelopmental disorder risk genes, cortical circuit function, and cognitive processing required for behavioral adaptions$891,191
R01 · FY2025 · MH
Development of therapeutic candidates for stimulant use disorder using AI-driven platform for focused drug discovery and accelerated development$811,876
R42 · FY2025 · DA
Preclinical development of a precision therapy for a monogenic mental health disorder$1,524,504
U01 · FY2024 · MH · contact PI
Intersection of causal neurodevelopmental disorder risk genes, cortical circuit function, and cognitive processing required for behavioral adaptions$891,191
R01 · FY2024 · MH
Myosin II regulation of actin dynamics and the selective vulnerability of methamphetamine- and opioid-associated memory$721,617
R01 · FY2024 · DA · contact PI
Drug Discovery for First-In-Class Myosin 10 Inhibitors as a Novel Target for Glioblastoma$475,793
R33 · FY2024 · NS · contact PI
Intersection of causal neurodevelopmental disorder risk genes, cortical circuit function, and cognitive processing required for behavioral adaptions$891,191
R01 · FY2023 · MH
Integrated Platform for Discovery and Validation of Probes that Restore Protein Expression in Single-Gene Causes of Autism and Related Disorders$774,212
R01 · FY2023 · MH
Myosin II regulation of actin dynamics and the selective vulnerability of methamphetamine- and opioid-associated memory$721,617
R01 · FY2023 · DA · contact PI
Drug Discovery for First-In-Class Myosin 10 Inhibitors as a Novel Target for Glioblastoma$497,954
R33 · FY2023 · NS · contact PI
Developing nonmuscle myosin II inhibitors for the treatment of glioblastoma$480,290
R33 · FY2023 · NS · contact PI
Myosin II regulation of actin dynamics and the selective vulnerability of methamphetamine- and opioid-associated memory$721,617
R01 · FY2022 · DA · contact PI
Integrated Platform for Discovery and Validation of Probes that Restore Protein Expression in Single-Gene Causes of Autism and Related Disorders$547,173
R01 · FY2022 · MH
Circuit-level substrates of ASD-related cognitive and behavioral impairments$376,284
R01 · FY2022 · MH
Developing nonmuscle myosin II inhibitors for the treatment of glioblastoma$322,231
R33 · FY2022 · NS · contact PI
Development of the AI-driven model for anti-SUD drug development based on neuronal plasticity$312,310
R43 · FY2022 · DA
Integrated Platform for Discovery and Validation of Probes that Restore Protein Expression in Single-Gene Causes of Autism and Related Disorders$295,695
R01 · FY2022 · MH
Circuit-level substrates of ASD-related cognitive and behavioral impairments$258,591
R01 · FY2022 · MH
Drug Discovery for First-In-Class Myosin 10 Inhibitors as a Novel Target for Glioblastoma$229,400
R61 · FY2022 · NS · contact PI
Preventing alcohol seeking with a nonmuscle myosin II inhibitor under clinical development$197,731
R21 · FY2022 · AA · contact PI
Drug Discovery for First-In-Class Myosin 10 Inhibitors as a Novel Target for Glioblastoma$185,371
R61 · FY2022 · NS · contact PI
Developing nonmuscle myosin II inhibitors for the treatment of glioblastoma$161,117
R33 · FY2022 · NS · contact PI
Myosin II regulation of actin dynamics and the selective vulnerability of methamphetamine- and opioid-associated memory$721,617
R01 · FY2021 · DA · contact PI
Circuit-level substrates of ASD-related cognitive and behavioral impairments$665,349
R01 · FY2021 · MH
Integrated Platform for Discovery and Validation of Probes that Restore Protein Expression in Single-Gene Causes of Autism and Related Disorders$652,164
R01 · FY2021 · MH
Developing nonmuscle myosin II inhibitors for the treatment of glioblastoma$351,725
R61 · FY2021 · NS · contact PI
Preventing alcohol seeking with a nonmuscle myosin II inhibitor under clinical development$267,975
R21 · FY2021 · AA · contact PI
Impact of prenatal opioid exposure on long-range brain circuit connectivity and behavior$231,250
R21 · FY2021 · DA · contact PI
Myosin II regulation of actin dynamics and the selective vulnerability of methamphetamine- and opioid-associated memory$721,617
R01 · FY2020 · DA · contact PI
Integrated Platform for Discovery and Validation of Probes that Restore Protein Expression in Single-Gene Causes of Autism and Related Disorders$668,094
R01 · FY2020 · MH
Circuit-level substrates of ASD-related cognitive and behavioral impairments$665,349
R01 · FY2020 · MH
Impact of prenatal opioid exposure on long-range brain circuit connectivity and behavior$277,500
R21 · FY2020 · DA · contact PI
Developing nonmuscle II inhibitors for substance use relapse$90,459
UH3 · FY2020 · NS · contact PI
Circuit-level substrates of ASD-related cognitive and behavioral impairments$745,594
R01 · FY2019 · MH
MiRNA-mediated mechanisms of long-term traumatic and non-traumatic memory storage$480,000
R01 · FY2019 · MH · contact PI
Developing nonmuscle II inhibitors for substance use relapse$180,291
UH3 · FY2019 · NS · contact PI
Developing nonmuscle II inhibitors for substance use relapse$90,459
UH3 · FY2019 · NS · contact PI
Circuit-level substrates of ASD-related cognitive and behavioral impairments$860,721
R01 · FY2018 · MH
Developing nonmuscle II inhibitors for substance use relapse$631,712
UH3 · FY2018 · NS · contact PI
MiRNA-mediated mechanisms of long-term traumatic and non-traumatic memory storage$480,000
R01 · FY2018 · MH · contact PI
Synaptic actin dynamics and the selective vulnerability of drug-associated memory$432,000
R01 · FY2018 · DA · contact PI
Developing nonmuscle II inhibitors for substance use relapse$148,694
UH3 · FY2018 · NS · contact PI
Developing nonmuscle II inhibitors for substance use relapse$622,212
UH3 · FY2017 · NS · contact PI
MiRNA-mediated mechanisms of long-term traumatic and non-traumatic memory storage$538,675
R01 · FY2017 · MH · contact PI
Synaptic actin dynamics and the selective vulnerability of drug-associated memory$432,000
R01 · FY2017 · DA · contact PI
Manipulating IncRNAs to Disrupt Reconsolidation of Methamphetamine Associated Memories$240,000
R21 · FY2017 · DA
Development of a whole-brain cellular mapping approach in a genetic model of autism and intellectual disability$198,000
R21 · FY2017 · MH
Developing nonmuscle II inhibitors for substance use relapse$638,362
UH2 · FY2016 · NS · contact PI
MiRNA-mediated mechanisms of long-term traumatic and non-traumatic memory storage$512,939
R01 · FY2016 · MH · contact PI
Synaptic actin dynamics and the selective vulnerability of drug-associated memory$442,914
R01 · FY2016 · DA · contact PI
Manipulating IncRNAs to Disrupt Reconsolidation of Methamphetamine Associated Memories$288,000
R21 · FY2016 · DA
Development of a whole-brain cellular mapping approach in a genetic model of autism and intellectual disability$269,000
R21 · FY2016 · MH
Synaptic actin dynamics and the selective vulnerability of drug-associated memory$516,298
R01 · FY2015 · DA · contact PI
MiRNA-mediated mechanisms of long-term traumatic and non-traumatic memory storage$480,000
R01 · FY2015 · MH · contact PI
Neurodevelopmental impact of prenatal exposure to prescription pain medication$236,400
R21 · FY2015 · DA · contact PI
Synaptic actin dynamics and the selective vulnerability of drug-associated memory$99,962
R01 · FY2015 · DA · contact PI
MiRNA-mediated mechanisms of long-term traumatic and non-traumatic memory storage$31,258
R01 · FY2015 · MH · contact PI
Synaptic actin dynamics and the selective vulnerability of drug-associated memory$425,250
R01 · FY2014 · DA · contact PI
Neurodevelopmental impact of prenatal exposure to prescription pain medication$236,250
R21 · FY2014 · DA · contact PI
Synaptic actin dynamics and the selective vulnerability of drug-associated memory$75,602
R01 · FY2014 · DA · contact PI
Synaptic actin dynamics and the selective vulnerability of drug-associated memory$425,250
R01 · FY2013 · DA · contact PI
A new addiction model: Relapse triggered by cognitive stress$95,040
R03 · FY2013 · DA · contact PI
Epigenetic Mechanisms of Memories Associated with Cocaine Reward$237,633
R00 · FY2012 · DA · contact PI
A new addiction model: Relapse triggered by cognitive stress$99,000
R03 · FY2012 · DA · contact PI
Epigenetic Mechanisms of Memories Associated with Cocaine Reward$244,908
R00 · FY2011 · DA · contact PI
Epigenetic Mechanisms of Memories Associated with Cocaine Reward$249,000
R00 · FY2010 · DA · contact PI
Epigenetic Mechanisms of Memories Associated with Cocaine Reward$105,768
K99 · FY2009 · DA · contact PI
Epigenetic Control of Learning and Memory$31,333
F32 · FY2008 · NS · contact PI
Epigenetic Control of Learning and Memory$46,207
F32 · FY2007 · NS · contact PI